Clinical Outcomes and Quality of Life after Patent Foramen Ovale (PFO) Closure in Patients with Stroke/Transient Ischemic Attack of Undetermined Cause and Other PFO-Associated Clinical Conditions: A Single-Center Experience
暂无分享,去创建一个
G. Novo | E. Onorato | S. Evola | Alessandro D’Agostino | O. F. Triolo | Emmanuele Antonio Camarda | Daniele Adorno | Giuseppina Novo | Eustaquio Maria Onorato | Alessandro D'Agostino
[1] Lin Li,et al. Pitfalls of Using Imaging Technique in the Presence of Eustachian Valve or Chiari Network: Effects on Right-to-Left Shunt and Related Influencing Factors , 2022, Diagnostics.
[2] A. Schwarz,et al. Obstructive Sleep Apnea (OSA) and Patent Foramen Ovale (PFO), the “Perfect Storm” for a Cryptogenic Stroke? Case Series of Four Patients , 2022, Frontiers in Stroke.
[3] Andrew J. Sims,et al. Patent foramen ovale closure: A prospective UK registry linked to hospital episode statistics , 2022, PloS one.
[4] Shota Saito,et al. Cost-effectiveness analysis of patent foramen ovale closure versus medical therapy alone after cryptogenic stroke , 2022, PloS one.
[5] Yajuan Du,et al. A Prospective, Single-Center, Phase I Clinical Trial to Evaluate the Value of Transesophageal Echocardiography in the Closure of Patent Foramen Ovale With a Novel Biodegradable Occluder , 2022, Frontiers in Cardiovascular Medicine.
[6] J. Carroll,et al. SCAI Guidelines for the Management of Patent Foramen Ovale , 2022, Journal of the Society for Cardiovascular Angiography & Interventions.
[7] Yu Cao,et al. Platelet P2Y12 Inhibitor in the Treatment and Prevention of Migraine: A Systematic Review and Meta-Analysis , 2022, Behavioural neurology.
[8] S. Malaisrie,et al. Chiari network and patent foramen ovale associated with stroke , 2021, JTCVS techniques.
[9] P. Germonpré,et al. Increased Risk of Decompression Sickness When Diving With a Right-to-Left Shunt: Results of a Prospective Single-Blinded Observational Study (The “Carotid Doppler” Study) , 2021, Frontiers in Physiology.
[10] E. Onorato. Large eustachian valve fostering paradoxical thromboembolism: passive bystander or serial partner in crime? , 2021, World journal of cardiology.
[11] H. Kamel,et al. 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. , 2021, Stroke.
[12] J. Carroll,et al. European position paper on the management of patients with patent foramen ovale. Part II - Decompression sickness, migraine, arterial deoxygenation syndromes and select high-risk clinical conditions. , 2021, European heart journal.
[13] Sabawoon Mirwais,et al. Patent Foramen Ovale With Platypnea – Orthodeoxia Syndrome: A Case Report , 2020, Cureus.
[14] A. Anselmi. Commentary: Patent foramen ovale is not always a benign condition , 2020, JTCVS techniques.
[15] C. Johnson,et al. Burden of Stroke in Europe , 2020, Stroke.
[16] P. Mitsias,et al. Patent Foramen Ovale in Cryptogenic Ischemic Stroke: Direct Cause, Risk Factor, or Incidental Finding? , 2020, Frontiers in Neurology.
[17] J. Carroll,et al. Practice advisory update summary: Patent foramen ovale and secondary stroke prevention , 2020, Neurology.
[18] P. Calvert,et al. Patent Foramen Ovale Closure: State of the Art , 2020, Interventional cardiology.
[19] É. Marijon,et al. Reprint of : Transcatheter closure of patent foramen ovale to prevent stroke recurrence in patients with otherwise unexplained ischaemic stroke: Expert consensus of the French Neurovascular Society and the French Society of Cardiology. , 2019, Revue neurologique.
[20] S. Kasner,et al. Cost-effectiveness of percutaneous closure of a patent foramen ovale compared with medical management in patients with a cryptogenic stroke: from the US payer perspective , 2019, Journal of medical economics.
[21] T. Villines,et al. Cost effectiveness and clinical efficacy of patent foramen ovale closure as compared to medical therapy in cryptogenic stroke patients: A detailed cost analysis and meta-analysis of randomized controlled trials. , 2018, International journal of cardiology.
[22] S. Kasner,et al. Evaluating the cost-effectiveness of percutaneous closure of a patent foramen ovale versus medical management in patients with a cryptogenic stroke: from the UK payer perspective , 2018, Journal of medical economics.
[23] T. Nazif,et al. Retrospective review of thienopyridine therapy in migraineurs with patent foramen ovale , 2018, Neurology.
[24] B. Meier,et al. European position paper on the management of patients with patent foramen ovale. General approach and left circulation thromboembolism. , 2018, European heart journal.
[25] Ayman Elbadawi,et al. Meta-analysis of randomized trials on percutaneous patent foramen ovale closure for prevention of migraine , 2018, Acta cardiologica.
[26] G. Chatellier,et al. Closure, Anticoagulation, or Antiplatelet Therapy for Cryptogenic Stroke With Patent Foramen Ovale: Systematic Review of Randomized Trials, Sequential Meta‐Analysis, and New Insights From the CLOSE Study , 2018, Journal of the American Heart Association.
[27] G. Sgueglia,et al. Novel percutaneous suture-mediated patent foramen ovale closure technique: early results of the NobleStitch EL Italian Registry. , 2018, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.
[28] J. Carroll,et al. Cost-Effectiveness of Patent Foramen Ovale Closure Versus Medical Therapy for Secondary Stroke Prevention , 2018, Stroke.
[29] Seung‐Jung Park,et al. Cryptogenic Stroke and High-Risk Patent Foramen Ovale: The DEFENSE-PFO Trial. , 2018, Journal of the American College of Cardiology.
[30] M. Dellborg,et al. Quality of life after percutaneous closure of patent foramen ovale in patients after cryptogenic stroke compared to a normative sample. , 2018, International journal of cardiology.
[31] J. Carroll,et al. Cost-effectiveness of percutaneous patent foramen ovale closure as secondary stroke prevention , 2018, Journal of medical economics.
[32] D. Holmes,et al. Coronary Embolus: An Underappreciated Cause of Acute Coronary Syndromes. , 2018, JACC. Cardiovascular interventions.
[33] S. Silberstein,et al. Percutaneous Closure of Patent Foramen Ovale in Patients With Migraine: The PREMIUM Trial. , 2017, Journal of the American College of Cardiology.
[34] Helle K. Iversen,et al. Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke , 2017, The New England journal of medicine.
[35] David E. Thaler,et al. Long‐Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke , 2017, The New England journal of medicine.
[36] S. Qureshi,et al. Interventions in Structural, Valvular and Congenital Heart Disease , 2015 .
[37] E. Loder,et al. The Prevalence and Burden of Migraine and Severe Headache in the United States: Updated Statistics From Government Health Surveillance Studies , 2015, Headache.
[38] M. Roffi,et al. Platypnea-orthodeoxia syndrome in the elderly treated by percutaneous patent foramen ovale closure: a case series and literature review. , 2013, European journal of internal medicine.
[39] D. Kent,et al. An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke , 2013, Neurology.
[40] Elizabeth Loder,et al. The Prevalence, Impact, and Treatment of Migraine and Severe Headaches in the United States: A Review of Statistics From National Surveillance Studies , 2013, Headache.
[41] R. Sterzi,et al. Wake-up stroke and TIA due to paradoxical embolism during long obstructive sleep apnoeas: a cross-sectional study , 2012, Thorax.
[42] E. Parati,et al. Microembolic Air Load During Contrast‐Transcranial Doppler: A Trigger for Migraine With Aura? , 2010, Headache.
[43] J. Ioannidis,et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. , 2009, Journal of clinical epidemiology.
[44] D. Dodick,et al. Patent Foramen Ovale and Migraine: A Quantitative Systematic Review , 2008, Cephalalgia : an international journal of headache.
[45] A. Dowson,et al. Migraine Intervention With STARFlex Technology (MIST) Trial: A Prospective, Multicenter, Double-Blind, Sham-Controlled Trial to Evaluate the Effectiveness of Patent Foramen Ovale Closure With STARFlex Septal Repair Implant to Resolve Refractory Migraine Headache , 2008, Circulation.
[46] Peter Wilmshurst,et al. The Role of Cardiac and Pulmonary Pathology in Migraine: A Hypothesis , 2006, Headache.
[47] R. Virmani,et al. Patent foramen ovale: current pathology, pathophysiology, and clinical status. , 2005, Journal of the American College of Cardiology.
[48] A. Angelini,et al. Intracardiac echocardiography: gross anatomy and magnetic resonance correlations and validations , 2005, The International Journal of Cardiovascular Imaging.
[49] Robert H. Anderson,et al. Development of the heart: (2) Septation of the atriums and ventricles , 2003, Heart.
[50] P. Wilmshurst,et al. Relationship between migraine and cardiac and pulmonary right-to-left shunts. , 2001, Clinical science.
[51] E. Zanette,et al. Detection of Right-to-Left Shunt with Ultrasound Contrast Agent and Transcranial Doppler Sonography , 2000, Cerebrovascular Diseases.
[52] F. Chédru,et al. Atrial Septal Aneurysm and Patent Foramen Ovale as Risk Factors for Cryptogenic Stroke in Patients Less Than 55 Years of Age: A Study Using Transesophageal Echocardiography , 1993, Stroke.
[53] J. Newburger,et al. Transcatheter Closure of Patent Foramen Ovale After Presumed Paradoxical Embolism , 1992, Circulation.